Trials / Completed
CompletedNCT00875485
Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™
An Open Multicentre, Multicountry Study to Evaluate Long-term Antibody Persistence and Immune Memory Between Years 11 and 15 After the Primary Study HAB-084 in Which Healthy Adolescents Were Vaccinated With Twinrix™ Adult Following a Two-dose Schedule or Twinrix™ Junior Following a Three-dose Schedule.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Years – 15 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the immune response against Hepatitis-A (HAV) and Hepatitis B surface (HBs) antigen in healthy subjects aged 12 to 15 years (at the time of primary vaccination), who received vaccination course with GSK Biologicals' Twinrix Adult and Twinrix Junior vaccine, approximately 10 years ago in the primary study. The subjects will be invited for blood sampling at 11, 12, 13, 14 and 15 years after primary vaccination to evaluate the persistence of immune response. For subjects detected with decreased immunity, the presence of immune memory against hepatitis A \& B antigens will be investigated by the administration of a challenge dose of the appropriate vaccine 6 to 12 months after the Year 15 follow-up time-point. No new subjects will be recruited during this booster phase of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood sampling | Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration. |
| BIOLOGICAL | Additional challenge dose | If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2009-04-03
- Last updated
- 2018-08-20
- Results posted
- 2010-07-05
Locations
2 sites across 2 countries: Belgium, Czechia
Source: ClinicalTrials.gov record NCT00875485. Inclusion in this directory is not an endorsement.